Ribavirin History

Ribavirin is a guanosine analogue that produces broad-spectrum activity against different RNA and DNA viruses. Four decades after its discovery this drug still proves useful for the treatment of a number of viral infections and may also be promising as an anticancer drug. Nevertheless, the uncertain nature of ribavirin’s antiviral mechanism of action has been a stumbling block to developing more efficacious derivatives for clinical usage.

The discovery of ribavirin

Ribavirin was first discovered and developed in 1970 by researchers from the International Chemical & Nuclear Corporation (ICN), today known as Valeant Pharmaceuticals. Chemists Joseph T. Witkovski and Ronald K. Robins had a main role in synthesizing this compound.

Ribavirin was initially approved for use in humans to treat pediatric respiratory syncytial virus infections. Through the years its efficacy for this indication has proved to be controversial, as shown in a number of studies with conflicting results.

In 1972 it was reported that ribavirin was active against different DNA and RNA viruses in culture systems and animals. Some examples were herpes simplex, vaccinia virus, measles, influenza A and B, parainfluenza, rhabdoviruses, arenaviruses, bunyaviruses and possibly retroviruses.

Research towards understanding the exact antiviral mechanism of ribavirin has a complex and contentious history, with a myriad of distinct mechanisms being proposed. In 2001 the mechanism was demonstrated by Craig E. Cameron, Shane Crotty and Raul Andino; their poliovirus experiments hinted that ribavirin's antiviral activity is exerted via lethal mutagenesis.

Severson and colleagues investigated the effect of ribavirin treatment on Hantaan virus. An observed decrease in viral mRNA and protein production was attributed to mutagenesis during transcription, leading to unstable or nonfunctional mRNAs. Moreover, a high number of insertions were found.

History of ribavirin usage in hepatitis C

First attempts to use ribavirin as monotherapy to treat hepatitis C was recorded in the early 1990s. Pilot studies were undertaken due to the fact that ribavirin previously demonstrated its broad-spectrum antiviral activity against RNA viruses, and that HCV is related to flavivirus with a positive sense RNA genome.

Patients treated with ribavirin monotherapy demonstrated improvements in serum alanine aminotransferase levels with certain indications that patients infected with HCV genotype 2/3 may be more responsive. On the other hand, little effect has been shown on HCV RNA levels, with no patients achieving viral clearance.

There were no other significant advancements in the treatment of hepatitis C until 1998, when the combination of ribavirin and interferon-alpha gained approval. Clinically, ribavirin showed a small, additive antiviral effect in combination with interferon, but its main effect was dose-dependent prevention of virological relapse.

Triple therapy regimens (i.e. the use of ribavirin with telaprevir and boceprevir) gained approval in May 2011. The role of ribavirin in success of this approach appeared to be on the prevention of relapse and the emergence of both low-level and high-level protease inhibitor resistance.

Sources

  1. http://www.liai.org/files/Ribavirin-Crotty.pdf
  2. chemeng.iisc.ernet.in/.../...f-ribavirin-against-hepatitis-c-virus.pdf
  3. www.researchgate.net/.../0a85e53a30ef818833000000.pdf
  4. www.researchgate.net/.../54461cee0cf22b3c14de06c2.pdf
  5. Rahman A, Choudhary MI. Frontiers in Anti-Infective Drug Discovery. Bentham Science Publishers, 2010; pp. 83-106.
  6. De Clerq E. Antiviral Drugs. In: Stromgaard K, Krogsgaard-Larsen P, Madsen U. Textbook of Drug Design and Discovery, Fourth Edition. CRC Press, 2009; pp. 393-418.

Further Reading

Last Updated: Aug 23, 2018

Dr. Tomislav Meštrović

Written by

Dr. Tomislav Meštrović

Dr. Tomislav Meštrović is a medical doctor (MD) with a Ph.D. in biomedical and health sciences, specialist in the field of clinical microbiology, and an Assistant Professor at Croatia's youngest university - University North. In addition to his interest in clinical, research and lecturing activities, his immense passion for medical writing and scientific communication goes back to his student days. He enjoys contributing back to the community. In his spare time, Tomislav is a movie buff and an avid traveler.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Meštrović, Tomislav. (2018, August 23). Ribavirin History. News-Medical. Retrieved on June 25, 2019 from https://www.news-medical.net/health/Ribavirin-History.aspx.

  • MLA

    Meštrović, Tomislav. "Ribavirin History". News-Medical. 25 June 2019. <https://www.news-medical.net/health/Ribavirin-History.aspx>.

  • Chicago

    Meštrović, Tomislav. "Ribavirin History". News-Medical. https://www.news-medical.net/health/Ribavirin-History.aspx. (accessed June 25, 2019).

  • Harvard

    Meštrović, Tomislav. 2018. Ribavirin History. News-Medical, viewed 25 June 2019, https://www.news-medical.net/health/Ribavirin-History.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post